Olopatadine ophthalmic solution

Olopatadine combines local H1-receptor antagonism with effects on mediator release in ocular allergy models. The represented evidence object is an ophthalmic solution placed directly on the eye. Its local route, local exposure, and current eye-itch label are the reason this is a separate page rather than another systemic H1-antihistamine entry.

In a double-masked randomized study, 10 people with seasonal allergic conjunctivitis used olopatadine in one eye and vehicle in the other before a conjunctival allergen challenge. Investigators measured tear histamine, inflammatory-cell counts, epithelial ICAM-1 expression, itching, and redness. Tear histamine and several other recorded endpoints differed between the treated and comparison eyes, supplying a measured human mediator-release bridge in a mast-cell-mediated condition rather than an MCAS outcome.

The current representative U.S. label is an over-the-counter ophthalmic product for temporary relief of itchy eyes attributed to listed environmental allergens. It describes olopatadine as an antihistamine and limits the product to external eye use. The catalog therefore places it under “Local-route symptom treatments,” not in the systemic maintenance sequence.